PLx Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLXP research report →
Companyplxpharma.com
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules.
- CEO
- Natasha Giordano
- IPO
- 2014
- Employees
- 16
- HQ
- Sparta, NJ, US
Price Chart
Valuation
- Market Cap
- $2.53M
- P/E
- -0.04
- P/S
- 0.31
- P/B
- 0.04
- EV/EBITDA
- 1.90
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 41.46%
- Op Margin
- -496.95%
- Net Margin
- -626.95%
- ROE
- -165.64%
- ROIC
- -62.98%
Growth & Income
- Revenue
- $8.21M · 26873.38%
- Net Income
- $-51,460,000 · -240.73%
- EPS
- $-2.18 · -40.65%
- Op Income
- $-40,790,000
- FCF YoY
- -160.16%
Performance & Tape
- 52W High
- $3.41
- 52W Low
- $0.01
- 50D MA
- $0.14
- 200D MA
- $0.56
- Beta
- 3.92
- Avg Volume
- 4.86M
Get TickerSpark's AI analysis on PLXP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 15, 22 | Giordano Natasha | buy | 4,100 |
| Mar 15, 22 | O'Connor Rita M | buy | 3,700 |
| Mar 15, 22 | O'Connor Rita M | buy | 10,000 |
| Feb 22, 22 | Valentino Michael J | other | 80,000 |
| Feb 22, 22 | O'Connor Rita M | other | 110,000 |
| Feb 22, 22 | HADDEN JOHN | other | 20,000 |
| Feb 22, 22 | Giordano Natasha | other | 300,000 |
| Feb 22, 22 | Casale Robert | other | 20,000 |
| Feb 22, 22 | CALHOUN KIRK K | other | 20,000 |
| Feb 22, 22 | Balkema Gary S. | other | 20,000 |
Our PLXP Coverage
We haven't published any research on PLXP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PLXP Report →